2-(1H-benzimidazol-2-ylthio)-1-thiophen-2-ylethanone is a chemical compound that is being investigated for its potential use in various research areas, particularly in the fields of:
**1. Anti-cancer Research:**
* **DNA intercalation:** This compound has shown to be capable of intercalating into DNA, which can disrupt the normal function of DNA and lead to cell death. This mechanism makes it a promising candidate for anti-cancer drug development.
* **Targeting specific cancer cells:** Studies have indicated that this compound may be selective in its action, targeting certain cancer cells while leaving healthy cells largely unaffected.
**2. Anti-inflammatory Research:**
* **Inhibition of inflammatory pathways:** This compound has exhibited anti-inflammatory properties by inhibiting the production of pro-inflammatory cytokines, which play a role in the development of inflammation.
**3. Anti-bacterial Research:**
* **Disrupting bacterial cell wall synthesis:** This compound has been shown to possess antibacterial activity, potentially by interfering with the synthesis of bacterial cell walls.
**4. Biological Activity Research:**
* **Understanding protein interactions:** This compound can be used as a probe to study protein interactions, which is crucial for understanding cellular processes and developing new drugs.
**Importance for Research:**
* **Potential therapeutic applications:** The diverse biological activities of 2-(1H-benzimidazol-2-ylthio)-1-thiophen-2-ylethanone make it a promising candidate for the development of new drugs for various diseases.
* **Understanding biological mechanisms:** This compound can be used as a tool to investigate the mechanisms of action of various biological pathways, contributing to a deeper understanding of cellular processes.
* **Drug discovery and development:** This compound can serve as a lead compound for the development of more potent and selective drugs with improved therapeutic properties.
**It's important to note that research on this compound is still ongoing, and further studies are needed to fully understand its potential therapeutic applications and safety profile.**
**Disclaimer:** I am an AI chatbot and cannot provide medical advice. The information provided above is for general knowledge and informational purposes only, and does not constitute medical advice. It is crucial to consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.
ID Source | ID |
---|---|
PubMed CID | 574171 |
CHEMBL ID | 1384293 |
CHEBI ID | 105693 |
Synonym |
---|
2-(1h-benzimidazol-2-ylsulfanyl)-1-thiophen-2-ylethanone |
EU-0019000 |
smr000059271 |
MLS000037705 , |
2-(1h-benzimidazol-2-ylsulfanyl)-1-(thiophen-2-yl)ethanone |
STK325629 |
AB00153907-05 |
HMS1649M04 |
AKOS001743299 |
HMS2345B13 |
2-((1h-benzo[d]imidazol-2-yl)thio)-1-(thiophen-2-yl)ethanone |
F0227-0176 |
22889-08-3 |
ethanone, 2-(2-benzimidazolylthio)-1-(2-thienyl)- |
2-(1h-benzimidazol-2-ylsulfanyl)-1-(2-thienyl)ethanone # |
HWDJEXQWGYZWTD-UHFFFAOYSA-N |
CHEMBL1384293 |
2-(1h-benzimidazol-2-ylthio)-1-thiophen-2-ylethanone |
Q27183450 |
SR-01000530135-1 |
sr-01000530135 |
2-(1h-1,3-benzodiazol-2-ylsulfanyl)-1-(thiophen-2-yl)ethan-1-one |
CHEBI:105693 |
2-(1h-benzimidazol-2-ylthio)-1-(2-thienyl)ethanone |
Class | Description |
---|---|
benzimidazoles | An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 5.6234 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 0.1585 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 0.1585 | 0.0251 | 20.2376 | 39.8107 | AID886 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 15.9323 | 0.0072 | 15.7588 | 89.3584 | AID411; AID588342 |
BRCA1 | Homo sapiens (human) | Potency | 0.3162 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 6.1590 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 25.1189 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 39.8107 | 0.7079 | 12.1943 | 39.8107 | AID720542 |
P53 | Homo sapiens (human) | Potency | 56.2341 | 0.0731 | 9.6858 | 31.6228 | AID504706 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 1.2589 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 9.2000 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 1.9953 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 39.8107 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
Vpr | Human immunodeficiency virus 1 | Potency | 11.2202 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 22.3872 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
AID1255663 | Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by WST-1 assay | 2015 | European journal of medicinal chemistry, Nov-02, Volume: 104 | 2-((Benzimidazol-2-yl)thio)-1-arylethan-1-ones: Synthesis, crystal study and cancer stem cells CD133 targeting potential. |
AID1255664 | Inhibition of cell surface expression of CD133 in human HT-29 cells at 10 uM by flow cytometric analysis relative to control | 2015 | European journal of medicinal chemistry, Nov-02, Volume: 104 | 2-((Benzimidazol-2-yl)thio)-1-arylethan-1-ones: Synthesis, crystal study and cancer stem cells CD133 targeting potential. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 7 (70.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.00) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |